Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.58 |
| ▸ | CNR2 | P34972 | 17/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545799 | 1.00 | CNR1 (0.58) | CNR1CNR2PTGS2 | |
| SCHEMBL2027212 | 1.00 | CNR1 (0.58) | CNR1CNR2PTGS2 | |
| SCHEMBL5916439 | 0.98 | CNR1 (0.56) | CNR1CNR2PTGS2 | |
| SCHEMBL4263013 | 0.92 | CNR1 (0.50) | CNR1CNR2PTGS2 | |
| SCHEMBL23461319 | 0.87 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL23461991 | 0.87 | CNR1 (0.48) | CNR1CNR2PTGS2 | |
| SCHEMBL10653170 | 0.87 | CNR1 (0.61) | CNR1CNR2PTGS2 | |
| SCHEMBL69216 | 0.84 | GABRA1 (0.46) | CNR1CNR2PTGS2 | |
| SCHEMBL10653359 | 0.83 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL23461361 | 0.83 | CNR1 (0.46) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | claimed |
| US-10450251-B2 | Process for the preparation of 3-substituted cannabinoid compounds | E-THERAPEUTICS PLC (GB) | 2019-10-22 | — | — | US | claimed |
| WO-2019079677-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CORBUS PHARMACEUTICALS, INC. (US) | 2019-04-25 | — | — | WO | claimed |
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2018-12-13 | — | — | US | claimed |
| EP-3383832-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | e-Therapeutics plc (GB) | 2018-10-10 | — | — | EP | claimed |
| WO-2017093749-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2017-06-08 | — | — | WO | claimed |
| EP-0004753-B1 | PREPARATION OF TETRAHYDROBENZOXOCINS AND CIS-HEXAHYDRODIBENZOPYRANONES | ELI LILLY AND COMPANY (US) | 1982-05-26 | — | — | EP | claimed |
| EP-0004753-A1 | Preparation of tetrahydrobenzoxocins and cis-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1979-10-17 | — | — | EP | claimed |
| US-4171315-A | Preparation of cis-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1979-10-16 | — | — | US | claimed |
| US-4148809-A | Process for preparing dl-cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones | ELI LILLY AND COMPANY (US) | 1979-04-10 | — | — | US | claimed |
| US-4131614-A | Process for preparing cis-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| US-4087410-A | 5-(Tertiary alkyl) resorcinol preparation and intermediates therefor | ELI LILLY AND COMPANY (US) | 1978-05-02 | — | — | US | claimed |
| US-4075230-A | Preparation of optically active trans-hexahydrodibenzopyranones | ELI LILLY AND COMPANY (US) | 1978-02-21 | — | — | US | claimed |
| US-4054581-A | Preparation of cis-1-hydroxy-3-substituted-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones and intermediates therefor | ELI LILLY AND COMPANY (US) | 1977-10-18 | — | — | US | claimed |
| US-20260007688-A1 | SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250236578-A1 | NOVEL CANNABINOID DERIVATIVES | CANNASOUL ANALYTICS LTD. (IL) | 2025-07-24 | — | — | US | disclosed |
| CN-113874344-B | Use of 8, 9-dihydro cannabidiol compounds | 加利福尼亚大学董事会 | 2025-05-27 | — | — | CN | disclosed |
| US-3962448-A | CNS DEPRESSANTS, VETERINARY | SMITHKLINE CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
| US-3953603-A | Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs | ELI LILLY AND COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3944673-A | Hexahydro-dibenzo[b,d]pyran-9-ones as analgesic drugs | ELI LILLY AND COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007688-A1 | SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS | AIFM2, FECH, NLN | CNR1 5/4885CNR2 4/4885PTGS2 600/4885 |
| US-20210198223-A1 | METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL | CNR1, DHCR24, CNR2 | CNR1 1/4885CNR2 3/4885PTGS2 2602/4885 |
| US-20250236578-A1 | NOVEL CANNABINOID DERIVATIVES | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885PTGS2 865/4885 |
| US-20180354876-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | CNR1, CNR2, OPRK1 | CNR1 1/4885CNR2 2/4885PTGS2 875/4885 |
| US-10450251-B2 | Process for the preparation of 3-substituted cannabinoid compounds | CNR1, CNR2, CBR1 | CNR1 1/4885CNR2 2/4885PTGS2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.